# Juventas Cell Therapy

Source: https://onco.cc/companies/juventas-cell-therapy/  
OnCo record `juventas-cell-therapy` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Juventas Cell Therapy in Tianjin developed inaticabtagene autoleucel, the first CAR-T approved in China for leukaemia (2023).

## Summary

Juventas Cell Therapy was founded in Tianjin with the Chinese Academy of Medical Sciences Institute of Hematology. Its CD19 CAR-T inaticabtagene autoleucel (CNCT19) was approved by the NMPA in November 2023 for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, and is also in trials for large B-cell lymphoma.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Hebei Senlang Biotechnology
- Tags: ctgov-sponsor; china
- HQ: Tianjin, China
- Type: cell-therapy
- Website: https://www.juventascell.com

## Sources

- Official website: https://www.juventascell.com

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- drugs: [Inaticabtagene autoleucel](https://onco.cc/drugs/inaticabtagene-autoleucel/)
- trials: [A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)](https://onco.cc/trials/nct05667506/), [Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct04684147/), [Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct04586478/)

---
JSON: https://onco.cc/api/v1/entities/juventas-cell-therapy.json